AAV9 Vectors Encoding MRTF-A and Tβ4 for Stable Neovascularization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for coronary heart disease and peripheral ischemia fail to effectively induce stable and regulated microvessel growth, leading to inadequate neovascularization and perfusion improvement in patients.
Innovation Solution
The use of adeno-associated viral vectors (AAV vectors) encoding myocardin-related transcription factor A (MRTF-A) and thymosin β4 (Tβ4), specifically pseudotyped with AAV9 envelope proteins, to promote angiogenesis and arteriogenesis by inducing microvessel maturation and collateral growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional gene therapy approaches are used to induce angiogenesis, then capillary growth is reinforced, but microvessel maturation and stable neovascularization are not achieved
Solution Approach 1:
The patent combines multiple proangiogenic factors (VEGF-A, PDGF-B, FGF-2) and maturation factors (angiopoietin-1, PDGF-B) into a single gene therapy vector system. This merging of multiple therapeutic agents addresses the contradiction by simultaneously promoting capillary growth and ensuring microvessel maturation, thereby achieving stable neovascularization that conventional single-factor approaches failed to accomplish.
Solution Approach 2:
The invention uses a composite vector system comprising AAV serotype 9 pseudotyped with cap protein and co-expressing multiple transgenes. This composite approach integrates different functional elements (angiogenesis promotion and maturation induction) into a unified therapeutic platform, resolving the contradiction between quantity of new vessels and their stability/maturation.
2Area of stationary object
If angiogenesis is reinforced without microvessel maturation, then capillary network expansion occurs, but functional neovascularization and perfusion improvement are inadequate
Solution Approach 1:
The patent employs preliminary action by first establishing capillary network expansion through proangiogenic factors, then immediately following up with maturation factors (angiopoietin-1, PDGF-B) to ensure proper vessel formation and stabilization. This sequential but integrated approach ensures that capillary expansion is followed by maturation, achieving functional neovascularization.
Solution Approach 2:
The gene therapy vector system incorporates feedback mechanisms where the expression of maturation factors is coordinated with angiogenesis promotion. The dual-transgene system ensures that as new capillaries form, maturation signals are simultaneously activated, creating a self-regulating system that balances vessel formation with stabilization.
3Reliability
If AAV vectors encoding MRTF-A and Tβ4 are used to promote angiogenesis, then microvessel maturation and collateral growth are induced, but vector complexity increases
Solution Approach 1:
The AAV serotype 9 vector system serves multiple functions simultaneously: it delivers proangiogenic factors, maturation factors, and targets specific vascular cells. This multi-functionality reduces the need for multiple separate vectors, thereby managing complexity while achieving comprehensive microvessel maturation and collateral growth.
Solution Approach 2:
The patent uses AAV serotype 9 as an intermediary vector that facilitates the delivery of complex genetic material to vascular cells. The pseudotyped cap protein enables efficient transduction while the vector backbone provides regulatory elements for controlled expression, acting as an intermediary that simplifies the delivery of multiple therapeutic genes.
Data Source
AI summary
The invention relates to the provision of a gene therapy for coronary heart disease and peripheral ischemia in mammals. One embodiment is an adeno-associated viral vector (AAV vector) comprising a first gene encoding a myocardin-related transcription factor A (MRTF-A). The invention further also relates to a pharmaceutical composition comprising an AAV vector of the invention and a pharmaceutically acceptable carrier. Methods for preparing the vector of the invention are also disclosed.